Kymera Therapeutics
KYMR
108.35
+2.37
+2.24%
Kymera Therapeutics
US · KYMR
#1580 by market cap
Listed 2020
108.35
+2.37
+2.24%
Live - 5344 symbols - heartbeat 309s ago
· 2026-10-08 04:01
Pre-market
108.35
0.00%
After-hours
106.00
-2.17%
- Market cap
- 9.01B
- P/E (TTM)i
- -33.34
- P/Bi
- 5.97
- EPSi
- -3.69
- Div yieldi
- 0.00%
- 52W posi
- 71%
Reader sentiment
Are you bullish or bearish on KYMR?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 15 analysts
Buy
Avg price target
141.60 +30.7%
Price target rangecurrent 108.35
Low112.00
Avg141.60
High180.00
Buy 87%
Hold 13%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | Citi | -- | BUY | 150.00 |
| 2026-09-28 | J.P. Morgan | -- | BUY | 140.00 |
| 2026-09-23 | Piper Sandler | -- | BUY | 140.00 |
| 2026-09-22 | Stifel | -- | BUY | 152.00 |
| 2026-09-14 | BofA Securities | -- | BUY | 144.00 |
| 2026-09-10 | Wolfe Research | -- | BUY | 180.00 |
| 2026-09-03 | J.P. Morgan | -- | BUY | 140.00 |
| 2026-08-30 | Guggenheim | -- | BUY | 170.00 |
| 2026-08-27 | Wells Fargo | -- | BUY | 151.00 |
| 2026-08-20 | Piper Sandler | -- | BUY | 140.00 |
| 2026-08-13 | Stifel | -- | BUY | 132.00 |
| 2026-08-07 | BofA Securities | -- | BUY | 123.00 |
| 2026-08-06 | CCORF | -- | BUY | 129.00 |
| 2026-08-06 | Wells Fargo | -- | BUY | 116.00 |
| 2026-08-06 | Morgan Stanley | -- | BUY | 135.00 |
| 2026-08-06 | Stifel | -- | BUY | 132.00 |
| 2026-08-06 | Citi | -- | BUY | 135.00 |
| 2026-08-06 | H.C. Wainwright | -- | BUY | 134.00 |
| 2026-08-06 | Barclays | -- | BUY | 139.00 |
| 2026-08-06 | J.P. Morgan | -- | BUY | 121.00 |
| 2026-08-05 | UBS | -- | BUY | 128.00 |
| 2026-08-05 | Citi | -- | BUY | 135.00 |
| 2026-08-05 | RBC Capital | -- | HOLD | 112.00 |
| 2026-07-29 | Deutsche Bank | -- | HOLD | 120.00 |
| 2026-07-28 | Guggenheim | -- | BUY | 135.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1 1
■ Upgrades■ Downgrades
- 1 upgrade vs 1 downgrade among tracked analyst rating changes.
- Most recent: Wolfe Research moved from Hold to Buy on 2026-09-10.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-10 | Wolfe Research | HOLD → BUY | 180.00 |
| 2026-08-05 | RBC Capital | BUY → HOLD | 112.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-05 | -- | ±9.97% | +1.04% (in line) |
| 2026/Q1 | 2026-04-30 | -- | ±10.06% | -0.54% (in line) |
| 2025/Q4 | 2026-02-26 | -- | ±11.48% | +4.80% (in line) |
| 2025/Q3 | 2025-11-04 | -- | ±15.68% | +0.32% (in line) |
| 2025/Q2 | 2025-08-11 | -- | ±19.29% | -7.24% (in line) |
| 2025/Q1 | 2025-05-09 | -- | ±23.69% | -2.27% (in line) |
| 2024/Q4 | 2025-02-27 | -- | ±18.73% | -14.45% (in line) |
| 2024/Q3 | 2024-10-31 | -- | ±18.67% | -3.15% (in line) |
| 2024/Q2 | 2024-08-07 | -- | ±22.91% | -2.68% (in line) |
| 2024/Q1 | 2024-05-02 | -- | ±13.70% | +0.17% (in line) |
| 2023/Q4 | 2024-02-22 | -- | -- | +4.71% |
| 2023/Q3 | 2023-11-02 | -- | -- | +4.59% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 04:01:21 · For reference only, not investment advice and not tailored to your situation.